| scholarly article | Q13442814 |
| P50 | author | Robert Cook-Deegan | Q30001862 |
| Mildred Cho | Q59750202 | ||
| P2093 | author name string | Subhashini Chandrasekharan | |
| Lauren C Sayres | |||
| Ashwin Agarwal | |||
| P2860 | cites work | Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers | Q24611865 |
| Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease | Q24618036 | ||
| Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci | Q24632266 | ||
| Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population | Q61847837 | ||
| A Noninvasive Test to Determine Paternity in Pregnancy | Q64386295 | ||
| A non-invasive test for prenatal diagnosis based on fetal DNA present in maternal blood: a preliminary study | Q79756571 | ||
| The impact of patenting on DNA diagnostic practice | Q80857650 | ||
| Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting | Q83395075 | ||
| In the public interest? | Q84633858 | ||
| Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy | Q85495453 | ||
| Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing | Q87413917 | ||
| DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study | Q30414408 | ||
| Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women | Q33917070 | ||
| DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study | Q34029044 | ||
| Gene patents and licensing: case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and Society | Q34050364 | ||
| Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing | Q34256640 | ||
| Can patents deter innovation? The anticommons in biomedical research | Q34465829 | ||
| Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome | Q34493495 | ||
| DNA patents and diagnostics: not a pretty picture | Q34520116 | ||
| Social and ethnic inequalities in the offer and uptake of prenatal screening and diagnosis in the UK: a systematic review. | Q35683514 | ||
| Noninvasive whole-genome sequencing of a human fetus. | Q36048523 | ||
| Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy | Q36406163 | ||
| Diagnostic testing fails the test | Q36417487 | ||
| Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma | Q36595101 | ||
| The dangers of diagnostic monopolies | Q37242063 | ||
| Women's perceptions of access to prenatal care in the United States: a literature review. | Q37467447 | ||
| The American Association of Birth Centers: history, membership, and current initiatives | Q37589860 | ||
| Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age | Q37809306 | ||
| Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. | Q40028555 | ||
| Cell-free fetal DNA testing: who is driving implementation? | Q44109756 | ||
| Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors | Q44274066 | ||
| Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood | Q44645735 | ||
| Beyond race or ethnicity and socioeconomic status: predictors of prenatal testing for Down syndrome | Q46163288 | ||
| Fetal tests spur legal battle | Q46299875 | ||
| Get ready for the flood of fetal gene screening | Q46556601 | ||
| Racial-ethnic differences in prenatal diagnostic test use and outcomes: preferences, socioeconomics, or patient knowledge? | Q46567892 | ||
| Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing | Q47758367 | ||
| Advances in prenatal screening: the ethical dimension. | Q48609420 | ||
| Putting patients before patents | Q48832379 | ||
| Testing for BRCA1 mutations: a cost-effectiveness analysis. | Q50708409 | ||
| Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. | Q51321305 | ||
| Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. | Q51349861 | ||
| Practical and ethical considerations of noninvasive prenatal diagnosis. | Q51933954 | ||
| Methods to Increase the Percentage of Free Fetal DNA Recovered From the Maternal Circulation | Q56001879 | ||
| Noninvasive prenatal tests for Down syndrome are near | Q56776996 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Survey confirms fears about licensing of genetic tests | Q59093046 | ||
| Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18 | Q61847821 | ||
| P433 | issue | 6 | |
| P921 | main subject | United States of America | Q30 |
| P304 | page(s) | 521-531 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Prenatal Diagnosis | Q15760059 |
| P1476 | title | Commercial landscape of noninvasive prenatal testing in the United States | |
| P478 | volume | 33 |
| Q35542250 | "Don't Want No Risk and Don't Want No Problems": Public Understandings of the Risks and Benefits of Non-Invasive Prenatal Testing in the United States |
| Q55173016 | "This lifetime commitment": Public conceptions of disability and noninvasive prenatal genetic screening. |
| Q35680437 | A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States |
| Q64260050 | A Silicon-based Coral-like Nanostructured Microfluidics to Isolate Rare Cells in Human Circulation: Validation by SK-BR-3 Cancer Cell Line and Its Utility in Circulating Fetal Nucleated Red Blood Cells |
| Q35447245 | Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. |
| Q38957119 | Clinical Versus Research Sequencing |
| Q37221717 | Comment on "Commercial landscape of noninvasive prenatal testing in the United States" |
| Q46914667 | Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women? |
| Q35841791 | Digynic triploidy: utility and challenges of noninvasive prenatal testing |
| Q27026343 | Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care? |
| Q58106704 | Ethical Concerns in the Implementation of DNA Sequencing-Based Noninvasive Prenatal Testing for Fetal Aneuploidy Among Obstetric Professionals in Hong Kong |
| Q35667111 | Exome Sequencing in Fetuses with Structural Malformations |
| Q89303078 | Genetic Counselors' Perspectives About Cell-Free DNA: Experiences, Challenges, and Expectations for Obstetricians |
| Q45283876 | Genomic testing reaches into the womb |
| Q24186694 | Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women |
| Q47618331 | Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. |
| Q58106669 | Hoping Someday Never Comes: Deferring Ethical Thinking About Noninvasive Prenatal Testing |
| Q91069740 | Identification of a de novo fetal variant in osteogenesis imperfecta by targeted sequencing-based noninvasive prenatal testing |
| Q93042108 | Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests |
| Q41829533 | Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States |
| Q38181003 | Lab-on-a-chip technology: impacting non-invasive prenatal diagnostics (NIPD) through miniaturisation |
| Q36311237 | Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. |
| Q26764809 | Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues |
| Q51012348 | Non-invasive prenatal testing for trisomy 21 based on analysis of cell-free fetal DNA circulating in the maternal plasma. |
| Q26999426 | Non-invasive prenatal testing: a review of international implementation and challenges |
| Q38549770 | Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA |
| Q46181819 | Noninvasive prenatal diagnosis of fetal aneuploidy by circulating fetal nucleated red blood cells and extravillous trophoblasts using silicon-based nanostructured microfluidics. |
| Q33957923 | Noninvasive prenatal testing goes global |
| Q48240788 | Noninvasive prenatal testing: the paradigm is shifting rapidly |
| Q55311725 | Online direct-to-consumer messages about non-invasive prenatal genetic testing. |
| Q51407385 | Open source non-invasive prenatal testing platform and its performance in a public health laboratory. |
| Q36586816 | PURLs: Aneuploidy screening: Newer noninvasive test gains traction |
| Q36107557 | Performance of Momguard, a new non-invasive prenatal testing protocol developed in Korea |
| Q93588821 | Position Statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing |
| Q33418571 | Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia - current status |
| Q58106679 | Printing Unrealistic Expectations: A Closer Look at Newspaper Representations of Noninvasive Prenatal Testing |
| Q36045923 | Rates of prenatal screening across health care regions in Ontario, Canada: a retrospective cohort study |
| Q48150074 | Recommended pre-test counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. |
| Q34295095 | Six consecutive false positive cases from cell-free fetal DNA testing in a single referring centre |
| Q35750561 | The Legal Past, Present and Future of Prenatal Genetic Testing: Professional Liability and Other Legal Challenges Affecting Patient Access to Services |
| Q63738815 | The continuing saga of patents and non‐invasive prenatal testing |
| Q47795103 | The use of noninvasive prenatal testing in obstetric care: educational resources, practice patterns, and barriers reported by a national sample of clinicians |
| Q26998800 | Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond |
| Q47953180 | Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context |
| Q58106651 | Unjustified: The Imbalance of Information and Funding With Noninvasive Prenatal Screening |
| Q38209384 | What does next-generation sequencing mean for prenatal diagnosis? |
| Q37333449 | Will the introduction of non-invasive prenatal testing for Down's syndrome undermine informed choice? |
| Q52319943 | Women's perspectives on the ethical implications of non-invasive prenatal testing: a qualitative analysis to inform health policy decisions. |
Search more.